Endocrine Abstracts

Pasireotide (Pas) is a multireceptor-targeted somatostatin analogue approved for the treatment of patients with Cushing’s Disease (CD) who fail or are poor candidates to surgery. Pas markedly improves signs and symptoms of the disease, reduces urinary free cortisol (UFC) up to its normalization in 55% of patients and pituitary tumour size in up to 100%. Here we present a patient with severe recurrent CD treated with Pas and showing opposite results between hormonal levels...

Introduction: Dopamine agonists are the first line treatment for prolactinomas. However, some patients may develop dopamine-agonist-resistant hyperprolactinemia, leading to surgery and/or radiotherapy. The persistence of hypogonadism requires testosterone replacement therapy which could theoretically reduce the efficacy of dopamine agonists due to the conversion of testosterone to estradiol, thus, in turn, increasing the resistance to dopamine agonists. Consequently, in these ...